Garekar Swati, Meeran Talha, Patel Vinay, Patil Sachin, Dhake Shyam, Mali Shivaji, Mhatre Amit, Bind Dilip, Gaur Ashish, Sinha Sandeep, Shetty Vijay, Sabnis Kirtis, Soni Bharat, Malankar Dhananjay, Mulay Anvay
Division of Pediatric Cardiology, Fortis Hospital, Mumbai, Maharashtra, India.
Division of Advanced Heart Failure, Cardiac Transplant and Pulmonary Hypertension, Fortis Hospital, Mumbai, Maharashtra, India.
Ann Pediatr Cardiol. 2020 Jul-Sep;13(3):220-226. doi: 10.4103/apc.APC_105_19. Epub 2020 Jul 2.
Pediatric heart transplantation is a now a well-established and standard treatment option for end stage heart failure for various conditions in children. Due to logistic issues, it is not an option for in most pediatric cardiac centres in the third world.
We sought to describe our early experience in the current era in India.
This is a short term retrospective chart review of pediatric patients who underwent heart transplantation at our centre. Mean/Median with standard deviation /range was used to present data.
Twenty patients underwent orthotopic heart transplant between January 2016 and June 2019. The median age at transplant was 12.4years (range 3.3 to 17.3 years). The median weight was 23.2kg (range 10-80kg). The mean donor/recipient weight ratio was 1.62± 0.84. The mean ICU stay was 12.1days. The mean follow up post transplant was 2.03± 0.97years (range 10 days-3.57years). The 1 month and the 1 year survival was 100%. Biopsies were positive for significant rejection in 7 patients (35%). At the time of last follow-up, 3 patients (15%) had expired. The major post transplant morbidities were mechanical circulatory support (n=3), hypertension with seizure complex (n=3), post transplant lympho-proliferative disorder (n=1), pseudocyst of pancreas (n=1), coronary allograft vasculopathy (n=3) and systemic hypertension (n=7). All surviving patients (n=17) were asymptomatic at last follow up.
The results suggest acceptable short term outcomes in Indian pediatric patients can be achieved after heart transplantation in the current era. Significant rejection episodes and coronary allograft vasculopathy need careful follow up.
小儿心脏移植现已成为治疗儿童各种终末期心力衰竭的成熟且标准的治疗选择。由于后勤问题,在大多数第三世界国家的儿科心脏中心,这并非一种可行的选择。
我们试图描述我们在印度当前时代的早期经验。
这是对在我们中心接受心脏移植的儿科患者进行的短期回顾性病历审查。数据采用均值/中位数及标准差/范围来呈现。
2016年1月至2019年6月期间,20例患者接受了原位心脏移植。移植时的中位年龄为12.4岁(范围3.3至17.3岁)。中位体重为23.2千克(范围10 - 80千克)。供体/受体平均体重比为1.62±0.84。平均重症监护病房停留时间为12.1天。移植后平均随访时间为2.03±0.97年(范围10天至3.57年)。1个月和1年生存率均为100%。7例患者(35%)的活检显示有明显排斥反应。在最后一次随访时,3例患者(15%)已死亡。主要的移植后并发症包括机械循环支持(n = 3)、伴有癫痫发作的高血压(n = 3)、移植后淋巴细胞增殖性疾病(n = 1)、胰腺假性囊肿(n = 1)、冠状动脉移植血管病变(n = 3)和系统性高血压(n = 7)。所有存活患者(n = 17)在最后一次随访时均无症状。
结果表明,在当前时代,印度儿科患者心脏移植后可取得可接受的短期疗效。明显的排斥反应发作和冠状动脉移植血管病变需要密切随访。